NCT01172717

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Phase II Study of Panitumumab in the Treatment of Carcinoid Syndrome

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Boston Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary hypothesis of this study is that panitumumab, an inhibitor of the epidermal growth factor receptor (EGFR), is an effective treatment for carcinoid syndrome in people who fail or do not adequately respond to octreotide or other supportive therapies.

Conditions

• Carcinoid Syndrome

Interventions

Type	Name	Description
DRUG	Panitumumab	Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2010-07-30
• Last updated: 2013-07-26

Locations

2 sites across 1 country: United States